JVM-2

Кат. номер

96090515-RNA-5UG

96090515-CDNA-20UL

96090515-DNA-5UG

96090515-1VL

Human Caucasian B-prolymphocytic leukaemia, EBV-transformed
JVM-2 has been derived from EBV and TPA treated mononuclear cells from a 63 year old female patient with B-prolymphocytic leukaemia. Thirty-three percent of cells were shown to be positive for surface lambda light chain, 37% for IgA, 29% for IgG and 3% for IgM and IgD. In addition, 50% were found to express cytoplasmic IgM and lambda light chain. Expression of the following leukocyte differentiation antigens was found: CD9, CD19, CD20, CD23, CD24, MA6, CD37, CD38, FMC1, FMC7, MHC Class I, FMC16, MHC Class II DR/DP/DQ. The immunoglobulin heavy-and light-chain genes showed the same pattern of rearrangement as in the original prolymphocytes. The cells are lymphoblastoid with large floating aggregates present. The cell line has been eradicated from mycoplasma at ECACC.
Ig expression of neoplastic cells
STR-PCR Data: Amelogenin: X
CSF1PO: 11
D13S317: 11,13
D16S539: 12,13
D5S818: 11,12
D7S820: 10,11
THO1: 6,9
TPOX: 8,11
vWA: 17
RPMI 1640 +2mM Glutamine + 10% Foetal Bovine Serum (FBS).
Maintain cultures between 3-9 x 100,000/ml; 5% CO2; 37°C.
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

biological source	human unknown/unspecified
growth mode	Suspension
karyotype	46,XX,-8,+t(3;8)(p12-13;q12),t(11;14)(q13;q32)
morphology	Lymphoblastoid
products	Not specified
receptors	Not specified
application(s)	cell culture | mammalian: suitable
relevant disease(s)	cancer
shipped in	dry ice
storage temp.	−196°C

RIDADR

NONH for all modes of transport